title: The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care.
abstract: OBJECTIVE
  This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).
  
  
  METHODS
  From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.
  
  
  RESULTS
  Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.
  
  
  CONCLUSIONS
  We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.
authors.affiliation: Division of Gastroenterology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Korea.
authors.forename: Hyuk Soo
authors.initials: HS
authors.lastname: Eun
authors.forename: Min Jung
authors.initials: MJ
authors.lastname: Kim
authors.forename: Hye Jin
authors.initials: HJ
authors.lastname: Kim
authors.forename: Kwang Hun
authors.initials: KH
authors.lastname: Ko
authors.forename: Hee Seok
authors.initials: HS
authors.lastname: Moon
authors.forename: Eaum Seok
authors.initials: ES
authors.lastname: Lee
authors.forename: Seok Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Heon Young
authors.initials: HY
authors.lastname: Lee
authors.forename: Byung Seok
authors.initials: BS
authors.lastname: Lee
mesh_terms: D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D016461:Chemoembolization, Therapeutic; D015331:Cohort Studies; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011379:Prognosis; D012189:Retrospective Studies; D012720:Severity of Illness Index; D016019:Survival Analysis; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins
references.citation: Am J Clin Oncol. 2006 Dec;29(6):568-75
references.pmid: 17148993
references.citation: Cancer. 2006 Apr 15;106(8):1653-63
references.pmid: 16541431
references.citation: Am J Clin Oncol. 1992 Aug;15(4):304-7
references.pmid: 1381143
references.citation: J Gastroenterol Hepatol. 1999 Oct;14(10):1025-33
references.pmid: 10530500
references.citation: Semin Liver Dis. 1999;19(3):329-38
references.pmid: 10518312
references.citation: Cancer. 2001 Jul 1;92(1):126-35
references.pmid: 11443618
references.citation: Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):393-7
references.pmid: 10030267
references.citation: Cancer. 1995 Nov 15;76(10):1737-46
references.pmid: 8625042
references.citation: Cancer. 1967 May;20(5):627-31
references.pmid: 4290385
references.citation: Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1067-76
references.pmid: 15913915
references.citation: Korean J Hepatol. 2009 Sep;15(3):391-423
references.pmid: 19783891
references.citation: Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):329-36
references.pmid: 12527045
references.citation: Gut. 2005 Mar;54(3):411-8
references.pmid: 15710992
references.citation: Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1143-50
references.pmid: 15752895
references.citation: Radiother Oncol. 2009 Aug;92(2):184-94
references.pmid: 19042048
references.citation: Semin Radiat Oncol. 2005 Oct;15(4):279-83
references.pmid: 16183482
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Int J Radiat Oncol Biol Phys. 1991 Mar;20(3):555-61
references.pmid: 1847363
references.citation: Am J Clin Oncol. 1982 Dec;5(6):649-55
references.pmid: 7165009
references.citation: Cancer. 1990 Nov 15;66(10):2174-9
references.pmid: 2171748
references.citation: Liver Int. 2006 Aug;26(6):680-7
references.pmid: 16842324
references.citation: Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9
references.pmid: 12909223
references.citation: Lancet. 1992 Aug 1;340(8814):285-8
references.pmid: 1353202
references.citation: Cancer. 2005 Jun 1;103(11):2419-26
references.pmid: 15822130
references.citation: Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):432-43
references.pmid: 15667964
references.citation: Hepatogastroenterology. 2003 Mar-Apr;50(50):500-3
references.pmid: 12749256
references.citation: Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):225-31
references.pmid: 17056199
references.citation: J Gastroenterol Hepatol. 2002 Feb;17(2):190-5
references.pmid: 11966950